Cannabis Dependence | Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders
Cannabis Dependence research study
What is the primary objective of this study?
This project tests the feasibility and utility of a novel, integrated approach to treatment of patients with cannabis use disorder (CUD) and anxiety disorders.
Who is eligible to participate?
Inclusion Criteria: 1. Diagnosis of cannabis use disorder 2. An additional diagnosis of an anxiety disorder 3. Patient reports that at least some of his/her cannabis use is aimed at reducing anxiety and/or for social facilitation. 4. Patient reports that cannabis is his/her substance of choice for anxiety management. 5. Concurrent use of psychotropic medications (e.g., selective serotonin reuptake inhibitors) is permitted as long as patients have been on a stable dose for at least three months prior to entering the study and they are willing to remain stable on their medication for the duration of treatment. 6. Age between 18 and 65 years. 7. English language fluency. 8. Willing and able to provide written informed consent. Exclusion Criteria: 1. Alcohol or illicit substance (non-cannabis) dependence. 2. Cannabis use behavior sufficiently uncontrolled that proper participation in study protocol would likely be disrupted. 3. History of schizophrenia, bipolar disorder, or organic brain syndrome. 4. Prominent suicidal ideation with intent that is judged to be clinically significant. 5. Mental retardation or another pervasive developmental disability (e.g., Asperger's Disorder). 6. Sufficiently socially unstable as to preclude completion of study requirements (e.g., homeless). 7. Prior simultaneous cognitive behavioral treatment for cannabis dependence and anxiety disorders. 8. Legally mandated to receive substance abuse treatment. 9. Report of current participation in or intent to participate in an additional (i.e., treatments other than MET-CBT or MET alone) anxiety or substance abuse treatment method during the course of the study. 10. Unwilling to maintain stable dose of regularly-dosed medications during the study 11. Unwilling to cease PRN (pro re nata or \"as needed\") use of benzodiazepines or other fast-acting anxiolytics prior to entrance into social situations.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Cannabis Use Disorder
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Behavioral:Motivation Enhancement Therapy
Behavioral:Integrated Cannabis and Anxiety Reduction Treatment
Behavioral:False Safety Behavior Elimination Therapy
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Cognitive-behavioral treatment program that integrates strategies to manage both cannabis use and anxiety with techniques to address motivation to change cannabis use.
Motivation/cognitive-behavioral therapyMotivational Enhancement Therapy (MET) and cognitive-behavioral therapy (CBT) that includes techniques to address motivation to change cannabis use with strategies to manage use.
Start Date: June 2013
Phase: Phase 1
Primary Outcome: cannabis use
Secondary Outcome: anxiety
Study sponsors, principal investigator, and references
Principal Investigator: Julia D Buckner, PhD
Collaborator: National Institute on Drug Abuse (NIDA)